• Revenue: Expected to rise 27.2% YoY to $3.082 billion, up from $2.42 billion in the same quarter last year.
• Earnings: Analysts expect a loss of 56 cents per share.
• Analyst Ratings: Current average rating is “hold”. Breakdown:
  • 2 “strong buy” or “buy”
  • 4 “hold”
  • 5 “sell” or “strong sell”
• Earnings Estimate Trend: Unchanged over the past three months.
• Price Target: Wall Street’s median 12-month price target is $13.00, roughly 35.8% below the last closing price of $17.66.

Summary: Oscar Health is expected to report strong revenue growth, but continued losses are anticipated. Market sentiment is mixed, reflected in the balanced analyst ratings and a price target significantly below the current stock price.